ARTICLE | Clinical News
Vatreptacog alfa: Development discontinued
October 1, 2012 7:00 AM UTC
Novo Nordisk discontinued development of vatreptacog alfa after data from the double-blind, international Phase IIIa adept 2 trial in 72 patients with congenital hemophilia and inhibitors showed that ...